C4 Therapeutics (CCCC) Short term Debt (2022 - 2023)
C4 Therapeutics (CCCC) recorded quarterly Short term Debt of $10.3 million in Q2 2023, up 351.9% quarter-over-quarter from $2.3 million in Q1 2023, and up 1278.0% on a YoY basis from $750000.0 in Q2 2022.
C4 Therapeutics (CCCC) Short term Debt (2022 - 2023) Analysis & Trends
C4 Therapeutics' Short term Debt history runs 2 years deep, the most recent figure standing at $10.3 million for Q2 2023.
- In Q2 2023, Short term Debt rose 1278.0% year-over-year to $10.3 million; the TTM figure through Jun 2023 stood at $10.3 million (up 1278.0% YoY), while the FY2022 annual figure was $2.3 million, changed N/A from the prior year.
- Short term Debt was $10.3 million for Q2 2023 at C4 Therapeutics, up from $2.3 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $10.3 million in Q2 2023 to a low of $750000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | C4 Therapeutics | 520.69 Mn | 285.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 10.34 Mn |
| Mar 31, 2023 | 2.29 Mn |
| Dec 31, 2022 | 2.29 Mn |
| Sep 30, 2022 | 2.25 Mn |
| Jun 30, 2022 | 750,000.00 |
| Mar 31, 2022 | 750,000.00 |